Sebastian Haferkampf

15PUBLICATIONS

103CO-AUTHORS

Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersAllergy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|Jul 01, 2026

Infusion-site reactions to foslevodopa/foscarbidopa in Parkinson's disease.

|May 27, 2026

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate.

|Apr 21, 2026

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Feb 27, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Michael Weichenthal, Dirk Debus, Lisa Zimmer

|Jan 20, 2026

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression.

Veronika Zenderowski, Laura Schreieder, Mark Berneburg

|Mar 06, 2025

Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

Pageof 3

Frequent Collaborators

Jochen Utikal

Dennis Niebel

Konstantin Drexler

Markus V Heppt

Michael Weichenthal

Roman Christoph Maron

Achim Hekler

Stefan Fröhling

Titus Josef Brinker

Eva Krieghoff-Henning

Frequent Collaborators

Jochen Utikal

Dennis Niebel

Konstantin Drexler

Markus V Heppt